NASDAQ: $AXSM Axsome Therapeutics, a leading biopharmaceutical company, has recently announced the exciting news that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the New Drug Application (NDA) for AXS-07 for the acute treatment of migraine. With the FDA acceptance of the NDA resubmission, Axsome Therapeutics is one step closer to…